PicoCELA Inc.
No enriched coverage for $PCLA in the last 7 days.
No SEC Form 4 filings for $PCLA in the last 30 days.
See all $PCLA insider activity →PicoCELA Inc. (PCLA) furnished an SEC Form 6-K — earnings release. Exhibit 99.2 MANAGEMENT’S SUPLEMENTAL EXPLANATION ON FINANCIAL RESULTS OF OPERATIONS Operating Results Comparison of the Results for the Six Months Ended March 31, 2026, 2025 and 2024 The following table sets forth statements of operations of PicoCELA Inc., a joint stock corporat
RH (NYSE:RH) shares rose 8.2% in pre-market trading after reporting Q2 earnings of $2.70 per share, beating estimates by 51.69%. Revenue was $922.15M, up from last year but below expectations. Other movers included Oracle (NYSE:ORCL), Alliance Entertainment (NASDAQ:AENT), and ACV Auctions (NYSE:ACVA).
PicoCELA shareholders approved a capital restructuring plan on February 24, 2026, including erasing ¥1.38 billion in accumulated deficit and expanding authorized shares to 16.6 million. These measures aim to strengthen the company's balance sheet and increase funding flexibility. Additionally, a 30-year restricted stock compensation program for directors was approved, designed to align their incentives with long-term corporate value.
Recent PCLA coverage spans financial news and earnings.
The large net loss and non‑cash compensation charge suggest weak operating performance and may pressure the share price.
Momentum continuation without fresh news.
The approval of capital restructuring and a long-term director stock plan suggests strategic efforts to strengthen PicoCELA's financial position and align management incentives with long-term growth. This could positively influence investor confidence and future performance.
The approval of a reverse stock split and director equity compensation by PicoCELA shareholders suggests strategic efforts to enhance market perception and align management incentives with shareholder value. The reverse split may temporarily boost stock price metrics, potentially attracting institutional interest, while director compensation aligns leadership interests with long-term shareholder value.
The investigation raises concerns about PCLA's stock, possibly leading to decreased investor confidence and a short-term price decline.
AlphAI scores every news story that mentions PCLA with an AI model for sentiment and relevance, and aggregates insider trades from PicoCELA Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
PicoCELA Inc. (PCLA) furnished an SEC Form 6-K — earnings release. Exhibit 99.2 MANAGEMENT’S SUPLEMENTAL EXPLANATION ON FINANCIAL RESULTS OF OPERATIONS Operating Results Comparison of the Results for the Six Months Ended March 31, 2026, 2025 and 2024 The following table sets forth statements of operations of PicoCELA Inc., a joint stock corporat
2 min readRH (NYSE:RH) shares rose 8.2% in pre-market trading after reporting Q2 earnings of $2.70 per share, beating estimates by 51.69%. Revenue was $922.15M, up from last year but below expectations. Other movers included Oracle (NYSE:ORCL), Alliance Entertainment (NASDAQ:AENT), and ACV Auctions (NYSE:ACVA).
3 min readPicoCELA shareholders approved a capital restructuring plan on February 24, 2026, including erasing ¥1.38 billion in accumulated deficit and expanding authorized shares to 16.6 million. These measures aim to strengthen the company's balance sheet and increase funding flexibility. Additionally, a 30-year restricted stock compensation program for directors was approved, designed to align their incentives with long-term corporate value.
2 min readPicoCELA Inc. shareholders approved a reverse stock split and director share compensation at their annual general meeting on December 29, 2025. The reverse stock split, taking effect January 26, 2026, will proportionally reduce outstanding shares and ADSs without impacting individual ADS holders' economic interests, aiming to support the company's market profile. Additionally, directors will receive share-based compensation, aligning their incentives with shareholder value.
2 min readSAN DIEGO, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- National law firm Morris Kandinov is investigating potential claims on behalf of victims of pump-and-dump schemes involving the following securities: Park Ha Biological Technology Co., Ltd. PHH. Top KingWin Ltd WAI. PicoCELA Inc.
4 min read
